OncoQuest wins $7.5 mln in round led by South Korean fund
Edmonton-based biopharmaceutical company OncoQuest Inc has raised about $7.5 million (US$6.03 million) in a private placement deal. It was led by an unidentified South Korean institutional fund. OncoQuest said that its existing investor Hepalink USA also converted its preferred shares and accrued 5 percent preferred-share dividends into common shares. OncoQuest is focused on developing immunotherapeutic products for treating cancer. Founded in 2015 and led by CEO Madi Madiyalakan, the company is a subsidiary of Quest PharmaTech Inc (TSX-V: QPT).
6 February 2018•3 mins read
